贝伐珠单抗联合热灌注化疗治疗晚期卵巢癌的临床效果及对TGF-β1、VEGF和MIF水平的影响

Efficacy of bevacizumab in the treatment of advanced ovarian cancer and its effect on the level of TGF-1,VEGF and MIF

目的探讨贝伐珠单抗联合热灌注化疗对晚期卵巢癌的临床效果及对血转化生长因子β1(TGF-β1)、血管内皮生长因子(VEGF)和巨噬细胞移动抑制因子(MIF)水平的影响。方法选取2014年8月至2015年12月间青岛市中心医院收治的114例晚期卵巢癌患者,根据治疗方法不同分为观察组59例和对照组55例。对照组患者采用热灌注化疗治疗,观察组患者在对照组基础上采用贝伐珠单抗治疗,比较两组患者治疗后的临床效果、不良反应发生情况、随访3年生存情况及治疗前后TGF-β1、VEGF和MIF指标水平。结果治疗后,观察组患者总有效率为88.1%,高于对照组的63.6%,差异有统计学意义(P<0.05)。治疗后,两组患者TGF-β1、MIF和VEGF指标均下降,且观察组低于对照组,差异均有统计学意义(均P<0.05)。两组患者治疗期间均发生白细胞下降、恶心呕吐、乏力、腹痛腹泻和骨髓抑制等不良反应,但发生率比较,差异无统计学意义(P>0.05)。随访结束后,观察组患者存活47例,死亡12例,对照组患者存活21例,死亡34例,两组比较,差异有统计学意义(P<0.05)。结论贝伐珠单抗联合热灌注化疗对晚期卵巢癌患者有较好的治疗效果,对TGF-β1、MIF和VEGF指标有抑制作用。

Objective To study the efficacy of bevacizumab in the treatment of advanced ovarian cancer and the effect on the level of vascular endothelial growth factor(TGF-1),vascular endothelial growth factor(VEGF)and macrophage migration inhibitory factor(MIF).Methods A total of 114 patients with advanced ovarian cancer treated at Qingdao Central Hospital from August 2014 to December 2015 were selected and divided into an observation group(59 patients)and a control group(55 patients)according to the different treatment methods they received.The observation group was treated with bevacizumab plus perfusion thermo-chemotherapy and the control group was treated with perfusion thermo-chemotherapy only.The treatment efficacy,the incidence of adverse reactions,3-year survival during the follow-up period and the levels of TGF-β1,VEGF and MIF before and after treatment were compared.Results After the treatment,the overall efficacy rate was 88.1%in the observation group which was significantly higher than63.6%of the control group(P<0.05).After the treatment,the indexes of TGF-β1,MIF,and VEGF decreased in both groups with the levels significantly lower in the observation group than in the control group(all P<0.05).Adverse reactions including neutropenia,nausea and vomiting,fatigue,abdominal pain diarrhea,and myelosuppression occurred in both groups.However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After the follow-up,47 patients and 21 patients were still alive and 12 patients and 34 patients died in the observation group and the control group,respectively(all P<0.05).Conclusion Bevalzumab combined with perfusion thermo-chemotherapy has significant therapeutic efficacy in patients with advanced ovarian cancer,and it has an inhibitory effect on TGF-β1,MIF and VEGF levels.